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their physicochemical properties and suitability for oral dosage forms. The development and
commercialization of dosage forms require analytical techniques that can determine and quantify the API
phase in the final drug product. 13C solid-state NMR (SSNMR) spectroscopy is widely employed to
characterize pure and formulated solid APIs; however, 13C SSNMR experiments on dosage forms with low
API loading are often challenging due to low sensitivity and interference from excipients. Here, fast MAS 1H
SSNMR experiments are shown to be applicable for the rapid characterization of low drug load formulations.
Diagnostic 1H SSNMR spectra of APIs within tablets are obtained by using combinations of frequency-
selective saturation and excitation pulses, 2D experiments and 1H spin diffusion periods. Selective saturation
pulses efficiently suppress the broad 1H SSNMR signals from the most commonly encountered excipients
such as lactose and cellulose, allowing observation of high-frequency API 1H NMR signals. 1H SSNMR
provides a one to three orders of magnitude reduction in experiment time compared to standard 13C SSNMR
experiments, enabling diagnostic SSNMR spectra of dilute APIs within tablets to be obtained within a few
minutes. The 1H SSNMR spectra can be used for quantification provided calibrations are performed on a
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ABSTRACT 
Active pharmaceutical ingredients (APIs) can be prepared in many different solid forms 
and phases that affect their physicochemical properties and suitability for oral dosage forms. The 
development and commercialization of dosage forms require analytical techniques that can 
determine and quantify the API phase in the final drug product. 13C solid-state NMR (SSNMR) 
spectroscopy is widely employed to characterize pure and formulated solid APIs; however, 13C 
SSNMR experiments on dosage forms with low API loading are often challenging due to low 
sensitivity and interference from excipients. Here, fast MAS 1H SSNMR experiments are shown 
to be applicable for the rapid characterization of low drug load formulations. Diagnostic 1H 
SSNMR spectra of APIs within tablets are obtained by using combinations of frequency-selective 
saturation and excitation pulses, 2D experiments and 1H spin diffusion periods. Selective 
saturation pulses efficiently suppress the broad 1H SSNMR signals from the most commonly 
encountered excipients such as lactose and cellulose, allowing observation of high frequency API 
1H NMR signals. 1H SSNMR provides a one to three orders of magnitude reduction in experiment 
time compared to standard 13C SSNMR experiments, enabling diagnostic SSNMR spectra of dilute 
APIs within tablets to be obtained within a few minutes. The 1H SSNMR spectra can be used for 
quantification provided calibrations are performed on a standard sample with known API loading. 
 
KEYWORDS 
Polymorph, Oral Dosage Forms, Phase Characterization, Active Pharmaceutical Ingredients, 
Molecular Structure 
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 3 
INTRODUCTION 
Active pharmaceutical ingredients (APIs) exist in numerous distinct solid phases (e.g., 
polymorphs, cocrystals, salts, amorphous dispersions, etc.) and their physicochemical properties 
determine the performance of the API within solid dosage forms such as tablets.1–3 13C cross-
polarization magic angle spinning (CPMAS) solid-state NMR (SSNMR) spectroscopy is widely 
applied for the identification, characterization, and quantification of pure and formulated solid 
APIs.4–7 Different solid API phases usually give rise to distinct 13C solid-state NMR spectra with 
unique 13C chemical shifts.4–7 However, the intrinsically poor sensitivity of natural isotopic 
abundance 13C SSNMR spectroscopy and the low concentration of APIs (typically 2 to 35 wt.%) 
often make it challenging to detect and characterize APIs in dosage forms by SSNMR. Prior 13C 
SSNMR studies of formulated drug products have shown that 13C SSNMR spectra diagnostic of 
the API phase can be acquired even for API loadings down to ca. 1 wt.% in favorable cases.7–11 
But, it is well known that APIs and organic solids can have long 1H longitudinal relaxation times 
(T1) on the order of hundreds of seconds.12–16 APIs with long 1H T1 will have substantially reduced 
sensitivity for 13C SSNMR and it is challenging or impossible to study such APIs by 13C SSNMR 
in formulations with low drug loads. Additionally, excipient materials in the formulation give rise 
to NMR signals that overlap/interfere with those from the API. Interference is especially 
problematic for 1H and 13C SSNMR experiments because most excipients are organic 
materials.17,18 Alternatively, NMR signals from the API can be selectively detected by probing 
NMR-active elements such as fluorine,19,20 nitrogen,17,21 sodium,22 and chlorine18,23 that are 
exclusive to the API. Unfortunately, these NMR experiments are often infeasible because of poor 
sensitivity and/or absence of these elements in the API.  
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 4 
Dynamic nuclear polarization (DNP)24–26 and fast magic angle spinning (MAS)27 are often 
employed to enhance the sensitivity of SSNMR experiments by orders of magnitude. DNP has 
provided order of magnitude gains in SSNMR sensitivity, enabling 13C, 15N, and 35Cl SSNMR 
experiments on a range of pure and formulated APIs.17,23,26,28,29 DNP is especially helpful for NMR 
experiments on APIs with long 1H T1.30,31 But, DNP currently requires specialized hardware, 
cryogenic sample temperatures and methods for doping the sample with stable radicals, which may 
cause unanticipated changes in the solid form of an API.32 The achievable DNP sensitivity 
enhancements are also highly sample dependent.17,23,26,28 
Fast MAS increases the sensitivity of SSNMR by providing access to high resolution 1H 
SSNMR spectra and/or enabling proton detection of heteronuclei.27,33,34 Fast MAS and/or 
homonuclear decoupling (i.e., CRAMPS) are routinely used to obtain high resolution 1H SSNMR 
spectra of pure APIs.4,5,34–40 Brown and co-workers applied CRAMPS double-quantum single-
quantum (DQ-SQ) 1H-1H 2D NMR experiments to differentiate hydrated and anhydrous forms of 
an API in a dosage form of unspecified API loading.41 They also showed fast MAS DQ-SQ 
experiments can detect and resolve minor polymorphic forms within mixtures of pure APIs down 
to a loading of 1 wt.%.42 Zhou and Rienstra have previously applied fast MAS and proton detection 
to obtain 2D 1H-13C HETCOR spectra of an ibuprofen tablet with high API loading (ca. 65 wt.%).43 
Though, proton detected 2D 1H{13C} SSNMR experiments are unlikely to provide significant 
gains in sensitivity as compared to direct detection 1D 13C CPMAS SSNMR with large diameter 
rotors.  
Here, we investigate the feasibility of using fast MAS 1H SSNMR experiments (νrot ≥ 50 
kHz) to rapidly detect and characterize dilute APIs in commercial and model dosage forms. 1H 
SSNMR offers much greater sensitivity than 13C SSNMR because of the 100% natural isotopic 
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 5 
abundance and high gyromagnetic ratio of 1H. To the best of our knowledge, fast MAS 1H SSNMR 
spectroscopy has not been demonstrated as a method to detect APIs in realistic dosage forms, likely 
because the limited resolution of 1H SSNMR spectra causes intense 1H NMR signals from the 
abundant excipients to overlap with and obscure the 1H NMR signals from the dilute API. To 
address this problem, we describe how 1H NMR signals from APIs in a formulation can be 
selectively detected by using pulse sequences that exploit combinations of selective excitation (SE) 
pulses, selective saturation pulses (SSPs) and spin diffusion (SD) periods. Comparison of fast 
MAS 1H and traditional 13C CPMAS SSNMR spectra shows that 1H SSNMR typically provides 
an order of magnitude reduction in experiment time. 1H solid-state NMR experiments on 
polymorphs and model formulations demonstrate that 1H solid-state NMR experiments can be used 
to detect different solid drug forms. The enhanced NMR sensitivity provided by 1H SSNMR is 
shown to be useful for experiments on formulations with low API loading and APIs that have long 
1H longitudinal relaxation times (T1).  
 
Experimental  
Sample Preparation. Pure API samples, lactose monohydrate, magnesium stearate, and 
microcrystalline cellulose (MCC) were purchased from Sigma-Aldrich and used without further 
purification. Commercial tablets of mecl (All Day Less Drowsy Dramamine-brand, 25 mg API 
dose, manufactured by Medtech Products Inc.), phenaz (Azo-brand, 97.5 mg API dose, 
manufactured by i-Health Inc.), phenyl (Sudafed PE-brand, 10 mg API dose, manufactured by 
McNeil Consumer Healthcare) were purchased from CVS Pharmacy. The API wt.% in the 
commercial tablets was determined by dividing the reported API dose by the total measured 
mass of the tablet (Table S1). Polymorphs of mexi were prepared from the as received mexi-I 
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 6 
according to previously reported syntheses,18,44 with some slight modifications. mexi-II was 
prepared by dissolving 100 mg of mexi-I in ca. 2 mL of methanol, then slowly recrystallizing 
mexi-II over a period of 5 days. Mexi-III was prepared by heating 100 mg of mexi-I at 160 °C 
in an oven for 2 hours. Model formulations were prepared for pheny (20.8 mg pheny, 276.8 mg 
MCC) and mexi (29.8 mg mexi-I, 5.81 mg mexi-III, 75.9 mg MCC) by thoroughly mixing the 
constituent powders in a vortex mixer for 5 minutes. Polymorphs of theo were prepared from the 
as received commercial sample of theo-II according to previously reported syntheses.32,45 theo-
M was synthesized by slowly recrystallizing 100 mg of theo-II in an excess of water. Normally, 
theo-I is obtained by holding theo-II at 270°C for 2 hours,45 however, with this procedure theo-
II was typically obtained. Instead, theo-I was obtained by holding theo-M at 270 oC for 2 hours. 
A model formulation of theo was prepared by thoroughly mixing 5 mg of theo-I, 9.8 mg of 
theo-II and 84.9 mg of MCC. 2 wt. %, 4 wt. % and 6.1 wt. % mixtures of theo-II in MCC were 
prepared by using the following masses for each component. 2 wt. % theo-II (2 mg theo-II in 
97.8 mg MCC). 4 wt. % theo-II (4 mg theo-II in 96.2 mg MCC). 6.1 wt. % theo-II (6.1 mg 
theo-II in 93.8 mg MCC).  
Solid-State NMR Spectroscopy. All samples were gently ground into a powder using a 
motor and pestle prior to packing into 1.3 mm or 4 mm zirconia rotors for solid-state NMR 
experiments. 1H and all 13C SSNMR experiments were performed on a 400 MHz (B0 = 9.4 T) 
Bruker Avance III HD spectrometer equipped with broadband double resonance HX 1.3 mm fast 
MAS and 4 mm HX probes. Additional 1H solid-state NMR (SSNMR) experiments were 
performed on a 800 MHz (B0 = 18.8 T) Bruker Avance III spectrometer at the National High 
Field Magnetic Laboratory (NHFML) in Tallahassee, Florida equipped with a Bruker triple 
resonance HCN 1.3 mm fast MAS probe. 1H SSNMR spectra were indirectly referenced to neat 
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 7 
tetramethylsilane (δiso = 0 ppm) using adamantane (δiso = 1.82 ppm) and the unified scale in the 
IUPAC standard.46  13C chemical shifts were referenced to neat tetramethylsilane (δiso = 0 ppm) 
by setting the high frequency peak of adamantane to 38.48 ppm.  All SSNMR spectra were 
processed using the TopSpin v3.5 software package. 
1H SSNMR experiments at both fields were performed with MAS frequencies of 50 kHz. 
See Figure S1 for the pulse sequences used in this work. Rotor-synchronized 1H spin echo (400 
MHz) or DEPTH47 (800 MHz) experiments were used to minimize background signals from the 
probes and rotor caps in 1D NMR spectra. 1H longitudinal relaxation time constants (T1) were 
measured with saturation recovery spin echo pulse sequences. The recycle delay for 1D NMR 
experiments was typically set to 1.3 or 5 times the 1H T1 measured for the pure API.  
2D 1H–1H spin diffusion (SD) NMR spectra were collected with (or without) selective 
saturation pulses (SSPs) (Figure S1). 2D SD NMR spectra were typically obtained with 4 scans 
per increment, t1 was incremented in steps of 40 µs (25 kHz indirect dimension spectral width). 
Typically 130 to 160 hyper-complex t1-increments were acquired, corresponding to respective 
acquisition times of 2.6 to 3.2 ms in the indirect dimension. Total experiment times are indicated 
on the various Figures. SSPs were applied on resonance with common excipient molecules (at 
ca. 3.5 ppm) saturated nearly all of the excipient 1H NMR signals with minimal effect on the 
high frequency NMR signals of the APIs (Figure S2). The SSP pulse length was 6 ms in all cases 
and the power and z-filter delay following the SSP (tZF) was directly optimized on each sample 
to suppress the excipient 1H NMR signals and minimize signal loss from high frequency API 
signals. tZF was between 20 µs and 20 ms depending on the sample, with shorter tZF used when 
1H spin diffusion between high and low frequency API signals was fast. The SSP typically used 
RF fields of less than 1 kHz. The SSP was typically applied at an offset of 3 – 4.5 ppm, near to 
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 8 
the peak maximum of MCC. However, at lower field, the SSP offset needs to be carefully 
optimized because 1H spin diffusion is likely more rapid (see Figure S19 for an example of 
optimization of the SSP offset). For 9.4 T experiments on mexi an alternative SSP condition was 
used: three 6 ms saturation pulses were applied at a transmitter frequency of ca. 2.9 ppm and 
each SSP was separated by spin diffusion periods (tSSP) of 20 ms. The 1D and 2D SD NMR 
experiments typically used spin diffusion delays between 5 and 70 ms. 1D selective-excitation 
spin diffusion (SE-SD) experiments were conducted at B0 = 18.8 T with a 600 µs low-power 
rectangular selective excitation pulse (ca. 400 Hz RF field) applied on resonance with high 
frequency API signals. The 1D SE-SD NMR spectra were obtained with the same pulse 
sequence as the 2D 1H–1H NOE experiments except without any evolution in t1 (Figure S1C). 
For experiments on theo at 9.4 T DANTE pulse trains48,49 were used for selective-excitation. The 
DANTE excitation pulses consisted of a train of fifteen 0.2 µs pulses, each separated by two 
rotor cycles (40 µs). The rf field of the 0.2 µs pulses was 85 kHz.  
All 13C MAS (νrot = 8 kHz) SSNMR experiments were performed at 9.4 T with a triple 
resonance Bruker HXY probe configured in double resonance mode to maximize sensitivity. 
MAS 13C SSNMR spectra were obtained with cross-polarization to enhance sensitivity.50 13C 
SSNMR spectra were acquired with the CP-TOSS sequence with a 243-step phase cycle.51,52 The 
1H CP spin lock pulse was linearly ramped between 90% and 100% of the spin lock RF field to 
broaden the Hartmann-Hahn match condition.53 The length of the contact pulse was between 1.5 
and 2.5 ms and was optimized on each sample. SPINAL-64 heteronuclear decoupling54 with an 
RF field of ca. 80 kHz was used for all 13C NMR experiments 
Powder X-ray diffraction. Powder X-ray diffraction was used to confirm that the mexi 
polymorph synthesis was successful (Figure S3). Powder X-ray Diffraction (PXRD) patterns of 
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 9 
all of the samples were obtained using a Rigaku Ultima U4 XRD, with a CuKα source (λ = 
1.540562 Å). A 2θ range of 5º to 50º was scanned in stepwise fashion (step size = 0.05º, dwell = 
2 seconds) for a total acquisition time of ca. 20 mins per sample. 
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Figure 1. Molecular structures of (A-B) common excipient molecules and (C-H) representative 
small molecules/APIs used in this work. 1D 1H SSNMR spectra of each compound are shown in 
the right column. All 1H SSNMR spectra were obtained with a 50 kHz MAS frequency at B0 = 
9.4 T. 
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RESULTS AND DISCUSSION 
Fast MAS 1H SSNMR Spectra of Representative APIs and Typical Excipients. Figure 1 shows 
the molecular structures of representative APIs investigated in this study. Molecular structures are 
also shown for commonly encountered excipients such as microcrystalline cellulose (MCC) and 
lactose. These excipients are the major components of many tablets.  Figure 1 and Figure S4 shows 
1H SSNMR spectra of the APIs and excipients obtained with a MAS frequency (nrot) of 50 kHz 
and B0 = 9.4 T (400 MHz 1H Larmor frequency). Inspection of Figure 1 shows that MCC and 
lactose give rise to relatively broad and featureless 1H NMR spectra that span a frequency range 
of ca. 0 to 7 ppm. The 1H SSNMR spectra of MCC and lactose are relatively featureless because 
they possess numerous hydroxyl protons and alkyl protons with similar 1H chemical shifts. On the 
other hand, many of the APIs have well-resolved, high frequency 1H NMR signals that are 
separated from the excipient 1H NMR signals. These high frequency 1H NMR peaks typically arise 
from hydrogen atoms in amine, ammonium, and carboxylic acid functional groups.33,37,40–42 The 
high frequency 1H NMR signals can be used to observe the 1H SSNMR spectra of the APIs within 
formulations. 
Page 11 of 36
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 12 
 
Figure 2. MAS 1H SSNMR spectra of pure mecl and a commercial 12.5 wt.% mecl tablet acquired 
at B0 = 18.8 T with νrot = 50 kHz. A) 1D DEPTH NMR spectra. B), C) 2D 1H SD NMR spectra 
acquired with a selective saturation pulse applied at 3.5 ppm and a 20 ms spin diffusion time. D) 
1H NMR spectra extracted from rows of the 2D NMR spectra (dashed lines in B and C).  
 
Fast MAS 1H SSNMR Spectra of Commercial Dramamine® Tablets. 1D 1H SSNMR 
experiments on the antihistamine API meclizine dihydrochloride (mecl, Figure 1) and a 
commercial Dramamine® Less Drowsy tablet with 12.5 wt.% mecl loading illustrate the 
challenges of obtaining 1H SSNMR spectra of an API within a low drug load formulation (Figure 
2A). The 1H SSNMR spectrum of the pure mecl obtained with a 50 kHz MAS frequency and B0 = 
18.8 T shows several distinct isotropic 1H chemical shifts, including a high frequency signal at 
12.7 ppm attributed to the ammonium group. The 18.8 T 1H SSNMR spectrum of the mecl tablet 
is dominated by the intense NMR signals from the excipient molecules, namely MCC. The intense 
MCC signals obscure most of the mecl signals; however, the 1H NMR signal of the ammonium 
group of mecl is resolved at 12.7 ppm (Figure 2A, inset). Protons with high chemical shifts are 
often involved in hydrogen bonding and are diagnostic of the solid form.33,37,40–42,55 The chemical 
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shift of the ammonium group is identical in the tablet and pure API, immediately suggesting the 
same API phase is present in both samples.  
Additional 1H NMR signals from the API may be required for phase identification, especially 
for APIs that can exist in multiple solid forms. Combinations of frequency-selective saturation and 
excitation pulses, 2D NMR spectra, and spin diffusion periods can be used to eliminate NMR 
signals from the excipients and obtain diagnostic 1H SSNMR spectra of the API in formulations. 
Under fast MAS, homonuclear 1H spin diffusion is slowed and resolved 1H NMR signals can be 
suppressed with selective saturation pulses (SSPs) which typically consist of long duration pulses 
(1 to 30 ms) with a low RF field (less than 2 kHz).56–58 The most commonly encountered excipient 
molecules have similar 1H chemical shifts in the solid-state, centered around 3-5 ppm (Figure 1), 
consequently, SSPs applied in this region will eliminate or attenuate signals from most excipients. 
Note that the broad, overlapped 1H SSNMR signals of MCC will lead to rapid 1H spin diffusion 
amongst the 1H spins in MCC, allowing the SSP to efficiently saturate the MCC 1H NMR signal. 
High frequency acid or amine peaks from APIs are typically between 8 and 20 ppm33,37,40–42 and 
are minimally affected by SSPs targeting the excipient resonances (Figure S2 and S4). Note that 
most APIs are marketed as free acids, salts, or cocrystals;59 therefore, APIs will usually possess 
amine, ammonium, or acid functional groups that give rise to high frequency 1H chemical shifts. 
2D 1H Spin Diffusion Experiments. 1D and 2D 1H spin diffusion (SD) NMR experiments36,60 
enhance resolution and provide access to additional 1H chemical shifts of the API (see Figure S1 
for pulse sequences). 2D 1H SD NMR experiments with SSPs were performed on pure mecl and 
the mecl tablet (Figures 2B and 2C). 2D 1H SD NMR spectra of the mecl tablet could also be 
obtained without SSPs because the ammonium peak is well resolved (Figures S6 and S7). 
However, SSPs are required to reduce excipient signals in most tablets. 1H spin diffusion occurs 
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during the delay (τSD) between the last two π/2 pulses, producing additional API peaks in the rows 
of the 2D NMR spectra. Spin diffusion only occurs between 1H nuclei that are proximate,61,62 
therefore, the NMR spectrum of the mecl tablet extracted from the ammonium peak row at 12.7 
ppm will only show 1H NMR signals from the API (dashed lines in Figure 2), assuming that the 
API is crystalline and phase segregated from the excipients. Figure 2D clearly shows that the same 
API phase is present in pure mecl and the mecl tablet, in agreement with 13C SSNMR experiments 
(see below).  The 1H SSNMR spectra obtained from the rows of the 2D spin diffusion spectra are 
distinct from the 1H spin echo NMR spectra because peak intensities depend upon the spin 
diffusion rates between the high frequency peak and the lower frequency peaks (cf. Figures 2A 
and 2D). For isolated spins, spectral spin diffusion rates are determined by the strength of the 
dipolar coupling of the two coupled spins and the peak overlap integral evaluated at zero 
frequency.63,64 The peak overlap integral is approximately inversely proportional to the square of 
the frequency difference.63,64 For example, the ammonium peak shows rapid spin diffusion to the 
positively shifted aromatic 1H NMR signals because the peaks have similar shifts and partially 
overlap at their baseline. On the other hand, the methyl and ammonium cross-peak has a low 
intensity and the cross-peak is negative. 1H spin diffusion between the methyl protons and 
ammonium groups is likely slow because methyl and ammonium peaks are well separated (∆δ ≈ 
11 ppm = 8.8 kHz at 18.8 T). Conventional ZQ spin diffusion (1H-1H flip-flop) causes positive 
cross-peaks. We therefore speculate that the negative ammonium-methyl cross-peak could be 
caused by a double-quantum nuclear Overhauser effect (DQ-NOE) and this will be the subject of 
future study.  
Notably, the 2D SD 1H NMR spectra were obtained in a few hours and experiment times could 
be further accelerated by reducing the spin diffusion time to focus the observed direct dimension 
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signal into fewer API peaks or by acquiring fewer increments in the 2D experiment (with the 
tradeoff of reduced resolution in the indirect dimension). The data shown in Figure 2 were acquired 
at B0 = 18.8 T, but 2D 1H SD NMR experiments with SSPs were also successful at B0 = 9.4 T 
(Figure S8). The selectivity of the SSPs for excipient saturation is generally better at high field 
because 1H spin diffusion is slowed by increased 1H shift dispersion. 
1D Spin Diffusion Experiments. If the chemical shift of a resolved API 1H NMR signal is known 
from prior characterization of pure API forms or from 1D 1H NMR experiments on the tablet, 1D 
selective excitation spin diffusion (SE-SD) NMR experiments can be performed (Figure S1C). In 
the 1D SE-SD NMR experiments on mecl, the ammonium peak at 12.7 ppm was selectively 
excited with a low-power 600 µs π/2 pulse. The transverse 1H ammonium magnetization was then 
reconverted to longitudinal magnetization by a high-power broadband π/2 pulse, which 
simultaneously saturates the other 1H NMR signals. The longitudinal 1H ammonium magnetization 
then undergoes spin diffusion for a fixed period of time, leading to the appearance of additional 
1H chemical shifts, which can then be read by a final broadband π/2 excitation pulse.  
The 1D SE-SD method produces a high quality 1H SD NMR spectrum of the mecl tablet in only 
30 minutes (Figure 3A). The 1D 1H SE-SD NMR spectrum of the mecl in the tablet obtained with 
a 70 ms spin diffusion time has a high signal-to-noise (SNR) ratio of ca. 44 for the characteristic 
ammonium peak, corresponding to a sensitivity (S) of 8.1 min–1/2 (S = SNR × t–1/2, where t is the 
total experiment time in minutes). Different pulse shapes or excitation schemes57,58,65 could likely 
improve the selectivity and efficiency of the SE pulses. For example, in later experiments on theo, 
simple DANTE schemes48,49 were used for efficient frequency-selective excitation.  
Comparison of 1H and 13C Solid-state NMR Spectroscopy. 1H SSNMR experiments provide 
much better sensitivity than conventional 13C CPMAS NMR experiments. A 13C CPMAS spectrum 
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of the mecl tablet was obtained with a 4 mm rotor and had a SNR of 17 after 2 hours of signal 
averaging (Figure 3C and Figure S9). For the 13C SSNMR experiments S = 1.6 min–1/2, while the 
1D 1H SSNMR spectrum of the mecl tablet had a S of 63 min–1/2 and the 1D 1H SE-SD spectrum 
had a S of 8.1 min–1/2 (Figure 3A and Figure S9). Comparing the sensitivity of the 1H and 13C 
SSNMR spectra shows that 1D 1H SSNMR offers 5– to 39–fold higher sensitivity for mecl, 
corresponding to 1 to 3 orders of magnitude reductions in experiment time as compared to 13C 
CPMAS. Note that the sensitivity of 1D SE-SD experiments could be further increased by reducing 
the 1H spin diffusion time to focus the NMR signal into fewer peaks, however, this would come at 
the expense of loss of intensity at other 1H chemical shifts. 
Figure 3. 1D 1H SE-SD and 13C CPMAS SSNMR spectra of A), C) pure mecl and a mecl tablet and B), 
D) pure phenaz and a phenaz tablet. The dashed line indicates the offset of the SE excitation pulse. Total 
experiment times are indicated. Spin diffusion times were 70 ms and 20 ms for mecl and phenaz, 
respectively. The 1H SSNMR spectra were acquired at B0 = 18.8 T with νrot = 50 kHz and 1.3 mm rotors. 
13C CPMAS spectra were obtained at B0 = 9.4 T with νrot = 8 kHz and 4 mm rotors. Experiment time (t), 
signal-to-noise ratio (SNR) and sensitivity (S) are indicated for each spectrum. The asterisks denote the 
peaks used for determination of (SNR) and calculation of S. 
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Characterization of Other Commercial Formulations. Fast MAS 1H SSNMR experiments were 
performed on other commercial API formulations to investigate the generality of our approach.  
1H and 13C SSNMR experiments on the API phenazopyridine hydrochloride (phenaz) and a 
commercial tablet with 68 wt.% API loading are summarized in Figures 3B and 3D (also Figures 
S10 and S11). Diagnostic 1H SSNMR spectra of phenaz in the tablet were obtained in a few 
minutes with the 1D SE-SD pulse sequence (Figure 3B). The similarity of the 1D SE-SD spectra 
of the pure phenaz and the phenaz tablet suggests the same API phase is present in both. The 1D 
SE-SD spectrum of phenaz in the tablet showed a SNR of 160 after 4.5 minutes of signal averaging 
(S = 75 min–1/2), demonstrating the improved sensitivity provided by 1H SSNMR spectroscopy. 
Comparing the 1D 1H SE-SD spectrum and the 13C CPMAS spectrum of the phenaz tablet shows 
that 1H SSNMR provides an order of magnitude improvement in sensitivity, corresponding to a 
100-fold reduction in experiment time. For example, consider a hypothetical 2 wt.% phenaz tablet: 
only 20 minutes would be required to obtain a 1D SE-SD 1H SSNMR spectrum with a SNR of ca. 
10, while ca. 4.5 days would be required to obtain a 13C CPMAS with similar SNR. 
The tablet Sudafed® PE containing 7 wt.% of the API phenylephrine hydrochloride (pheny) 
was also studied (Figure S12-S15). This tablet is challenging to characterize because it has a low 
API loading, pure pheny has a relatively long 1H T1 of 18 s, and the API protons are present in a 
secondary ammonium group (C2NH2+) containing 1H spins that are strongly dipolar coupled, 
leading to broadening of the high frequency API 1H NMR signals. The secondary ammonium 
protons also have chemical shifts at ca. 10 ppm, close to the 1H chemical shift of many excipients. 
The overlapped 1H NMR signals make it challenging to selectively saturate the excipients, 
resulting in reduced intensity of the high frequency API signals. Despite these challenges, 2D 1H 
SSNMR spectra of the pheny tablet were obtained in 7 hours at B0 = 9.4 T, while a 13C CPMAS 
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NMR spectrum of similar quality was obtained after 16 hours of signal averaging (Figures S15). 
Comparison of the 13C CPMAS spectra of pure pheny and the tablet suggest that the API is likely 
amorphous in the tablet. This is reflected in the distinct appearance of the 1H SSNMR spectra of 
the pheny tablet and pure pheny. In contrast, a model 7 wt.% pheny formulation made of a 
physical mixture of crystalline pheny and MCC yielded 1H SSNMR spectra consistent with the 
crystalline phase (Figure S14). The experiments on pheny illustrate that 1H SSNMR experiments 
are challenging when the 1H NMR spectrum of the API suffers from overlap of many 1H NMR 
signals and does not possess a well-resolved, high frequency 1H NMR signal. In such cases 13C 
CPMAS will likely be the preferred NMR method for interrogating the API phase within the tablet.  
 
Figure 4. 1H and 13C CPMAS SSNMR spectra of theophylline form I (theo-I), theophylline 
monohydrate (theo-m), and theophylline form II (theo-II). 1H SSNMR spectra were obtained with 
a 50 kHz MAS frequency at B0 = 9.4 T. 13C SSNMR spectra were obtained with a 8 kHz MAS 
frequency at B0 = 9.4 T. Dashed lines are guides for the eye to illustrate the differences in isotropic 
chemical shifts. 
 
Detection of Polymorphic Forms. It is well known that both 1H chemical shifts37,39,40,55,66,67 and 
SD rates33,35,66 are very sensitive to differences in solid-state structure. Therefore, 1H SSNMR 
should be an ideal technique to detect different API phases within formulations. To test this 
hypothesis, polymorphs of theophylline (theo) and mexiletine hydrochloride (mexi) and model 
 15  10  5  0 
1H Chemical Shift (ppm)
 30  160  150  140  130  120  110  100 
13C Chemical Shift (ppm)
theo-M
theo-I
theo-II
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formulations were characterized by 1H SSNMR. In addition to demonstrating the utility of our 
techniques to detect distinct solid phases in formulations, a critical aspect of pharmaceutical 
product development, these case studies provide examples of potential challenges for 1H SSNMR 
(i.e., slow 1H longitudinal relaxation and poor separation of the high frequency API peaks from 
the excipients), and methods that can be used to overcome them. 
Characterization of Theophylline Polymorphs. Theo has several stable crystal forms and a 
monohydrate  form, all of which are readily accessible by simple recrystallization procedures.32,45 
MAS 1H and 13C SSNMR spectra of theophylline form II (theo-II), theophylline form I (theo-I) 
and theophylline monohydrate (theo-m) are shown in Figure 4. The similarity of the 1H and 13C 
SSNMR spectra to those previously reported for the different polymorphs confirms the identity 
and purity of each polymorph.32 The 1D 1H SSNMR spectra of the different theo forms illustrates 
that all forms are easily distinguished on the basis of the distinct 1H chemical shifts observed for 
the amine (12-15 ppm) and methine (CH) protons (7.5-8.5 ppm). Baias et al. have noted that the 
differences in amine 1H chemical shift occurs because of the distinct hydrogen bonding motifs 
encountered in the different crystal forms.39 The single crystal X-ray structure of theo-II shows 
the NH group forms a hydrogen bond to the nitrogen atom in the five-membered purine ring of an 
adjacent theophylline molecule.45 The NH group forms a hydrogen bond to a carbonyl group of an 
adjacent theophylline molecule in both theo-m and theo-I.45  
1H T1 measurements were performed on the different pure theo forms with both slow (nrot = 8 
kHz) and fast MAS (nrot = 50 kHz) frequencies. Under slow MAS each 1H NMR signal showed a 
similar mono-exponential T1 because 1H spin diffusion is rapid between all 1H spins (Figure S16). 
The 1H T1 was ca. 53 s for theo-I and 64 s for theo-II (Table S2). Under fast MAS each 1H NMR 
signal had a distinct T1; for both theo forms the T1 of the methyl 1H was on the order of 60 s, while 
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the T1 of the high frequency amine 1H was much longer and between 300 – 460 s for the different 
forms (Table S3). The long 1H T1 for the amine 1H of theo arises with fast MAS because 1H spin 
diffusion has been slowed68 and there are likely no dynamic motions of the amine groups at the 
correct frequencies to cause longitudinal relaxation. Fast MAS could reduce the sensitivity of SD 
1H SSNMR experiments on theo where the amine signal will be excited because the amine 1H T1 
of several hundred seconds will dictate the recycle delay. Note that for the other compounds 
examined there were only slight differences in T1 measured for the different 1H NMR signals. 
Previously, Taulelle and Nishiyama showed that RFDR recoupling can be applied to accelerate 
1H spin diffusion under fast MAS and reduce the differences in 1H T1 between resolved 1H NMR 
signals.68 Alternatively, spin-lock pulses have been used to accelerate 13C spin diffusion when 
there is a large isotropic chemical shift difference.69 Here a low power 1H spin-lock pulse (ν1(1H) 
≈ 15 kHz) with a duration of a 1.8 ms was used to enable 1H spin diffusion across the entire theo 
1H NMR spectrum and transfer magnetization from the methyl 1H to the amine and methine 1H. 
The spin-lock pulse shortens the effective T1 of high frequency theo amine 1H NMR signals from 
several hundred seconds to less than 90 seconds (Table S3). Therefore, a 1H broadband π/2 
excitation pulse, spin-lock pulse, flip-back π/2 pulse block was inserted prior to any SE pulses in 
the subsequent 1H SSNMR experiments on theo (Figure S1). For 1D SE-SD experiments on theo 
a spin-lock pulse was used to promote 1H spin diffusion in lieu of the usual longitudinal 
magnetization storage period (Figure S1E). Spin-lock pulses used to accelerate 1H spin diffusion 
in theo were between 600 µs and 1.8 ms in duration. 
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Figure 5. 1H and 13C SSNMR spectra of a physical mixture of 85 wt.% MCC, 10 wt.% theo-II 
and 5 wt.% theo-I. 1H spin echo spectra recorded A) without and B) with SSP on resonance with 
MCC. (C-F) 1D SE-SD 1H SSNMR spectra with the SE pulse on resonance with the high 
frequency amine 1H NMR signal of (C, D) theo-I or (E, F) theo-II.  1H SSNMR spectra in D) and 
F) were obtained with a 1.8 ms spin-lock pulse following the SE pulse to promote 1H spin 
diffusion. Spectra in C) and E) were recorded with a 20 µs spin-lock pulse to minimize 1H spin 
diffusion. 1H SSNMR spectra were obtained with a 50 kHz MAS frequency at B0 = 9.4 T. 13C 
SSNMR spectra were obtained with an 8 kHz MAS frequency at B0 = 9.4 T. Experiment times (t), 
signal-to-noise ratios (SNR) and sensitivity (S) are indicated. The asterisks denote the peaks used 
for determination of (SNR) and calculation of S. 
Page 21 of 36
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 22 
NMR experiments were performed on mixtures of theo solid forms and MCC to 
demonstrate the potential of fast MAS 1H SSNMR to rapidly detect different solid API forms when 
they are dilute within a formulation. A mixture consisting of 85 wt.% MCC, 10 wt.% theo-II and 
5 wt.% theo-I was used in these initial experiments. This mixture mimics a scenario where there 
is a total drug load of 15 wt.% in the formulation and one-third of the API (theo-II) has undergone 
a transition to a secondary API phase (theo-I). In the 1D 1H SSNMR spectrum obtained without 
SSPs, the high frequency amine signals of both theo-I and theo-II are obscured (Figure 5A, inset). 
Acquisition of a 1D 1H SSNMR spectrum with SSPs helps suppress the MCC signals and clearly 
shows both amine and methine 1H NMR signals for both theo forms (Figure 5B).  
1D SE-SD NMR experiments were also performed with DANTE SE pulses on resonance 
with the amine signal of theo-I or theo-II (Figures 5C-5F). The 1D SE-SD 1H SSNMR spectra 
obtained with a minimal spin diffusion time only show the respective amine chemical shifts 
(Figures 5C and 5E), while those recorded with a 1.8 ms spin-lock pulse to promote 1H spin 
diffusion show additional chemical shifts from the methine and methyl groups (Figures 5D and 
5F). The 1H chemical shifts observed in the 1D SE-SD NMR spectra exactly match those observed 
in the 1H NMR spectra of the corresponding pure phases (Figure 4), confirming the identity of the 
theo phases in the mixture. 
Comparing the sensitivity of 13C and 1H SSNMR experiments on the theo-MCC mixture 
shows that 1H SSNMR once again provides far superior sensitivity. After 5 hours of signal 
averaging the 13C CPMAS spectrum of the mixture shows SNR of about 14 and 7 for characteristic 
13C peaks of theo-II and theo-I, respectively. These SNR values correspond to a sensitivity of 0.8 
min–1/2 and 0.4 min–1/2 for theo-II and theo-I, respectively. Note that the low sensitivity of 13C 
CPMAS for theo primarily arises because of its relatively long 1H T1 which requires a long recycle 
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delay over 1 minute to be used for optimal sensitivity. Despite the long 1H T1, 1H SSNMR spectra 
of both theo forms within the mixture can be obtained in 15 – 30 minutes with a SNR of over 30. 
The sensitivity of the 1H SSNMR spectra recorded without any spin diffusion is 13 min–1/2 and 5 
min–1/2 for theo-II and theo-I, respectively. The sensitivity provided by 1H SSNMR is about 16 
times better than 13C CPMAS, corresponding to a two order of magnitude reduction in experiment 
time. This is why high quality 1H NMR spectra are obtained in only 15-30 minutes each, while the 
13C CPMAS spectrum required hours of signal averaging.  
The SSNMR experiments on the theo-MCC mixture illustrate why it is challenging to 
characterize formulations with low API loading by conventional 13C CPMAS. For example, 
consider a scenario where the theo-II loading is only around 2 wt.%, then approximately 2.5 days 
of signal averaging would be required to obtain a 13C SSNMR spectrum with a SNR of 10. On the 
other hand, in only 30 minutes a 1H SSNMR spectrum of a 2 wt.% mixture of theo-II in MCC 
with a SNR of about 18 was obtained (Figure S17). This example demonstrates the advantages of 
fast MAS 1H SSNMR for probing formulations with very low API loading and/or when the API 
possesses a long 1H T1. 
Detection of Mexiletine Polymorphs. Three polymorphic forms of mexiletine 
hydrochloride (mexi), referred to as mexi-I, mexi-II, and mexi-III, were also prepared and 
characterized by 1H SSNMR. These polymorphs have previously been characterized with X-ray 
diffraction as well as 13C and 35Cl SSNMR.18,44 The distinct 1D 1H SSNMR spectra of the mexi 
polymorphs at B0 = 9.4 T suggests that 1H NMR should be useful to distinguish and quantify the 
different forms (Figure 6 and Figure S18). A model mexi formulation was prepared by mixing 5.2 
wt.% mexi-III, 26.7 wt.% mexi-I, and 68.0 wt.% MCC (total API load of 32 wt.%). The model 
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mexi formulation mimics the composition of a tablet with 16% of the API converted to a secondary 
phase (mexi-III).  
The mexi formulation is challenging to study by 1H SSNMR because the primary ammonium 
protons of mexi have chemical shifts of ca. 8 ppm, near to the 1H shifts of MCC. Therefore, SSP 
conditions that can completely saturate MCC signals and minimally perturb the mexi signals are 
required. Optimization of the SSP offset for mexi-I, mexi-III and MCC at B0 = 9.4 T showed that 
with a single SSP, the MCC signals can only be saturated when the SSP is applied at offsets of ca. 
4.7 to 3.7 ppm, which falls within the MCC lineshape (Figure S19A). However, at these offsets 
the 1H NMR signals from mexi-I and mexi-III are also partially saturated, likely because the mexi 
1H SSNMR spectra are poorly resolved at 9.4 T and 1H spin diffusion rapidly equilibrates 
polarization across the spectrum. 
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Figure 6.  (A-D) 1D 1H spin echo SSNMR spectra of MCC, the model mexi formulation, mexi-
III and mexi-I. The mexi formulation consists of a physical mixture of 5.2 wt.% mexi-III, 26.7 
wt.% mexi-I, and 68.0 wt.% MCC. Vertical dashed lines are guides for the eye to illustrate 
differences in 1H chemical shifts for the two mexi polymorphs. (E-H) 2D 1H SD NMR spectra of 
of MCC, the model mexi formulation, mexi-III and mexi-I. All spectra were recorded with a 20 
ms spin diffusion mixing time and three SSPs applied at an offset of 2.8 ppm. (I-L) 1H SSNMR 
spectra extracted from the indicated rows of the 2D 1H SD NMR spectra. Only 1H NMR signals 
from mexi-III are visible from the formulation. 
 
Alternatively, application of three SSPs, each separated by a 20 ms z-filter/spin diffusion period, 
enables MCC signals to be saturated completely with SSP offsets of 2.0 to 5.0 (Figure S19B). 2D 
1H SD NMR spectra acquired with SSP offsets below 3.0 ppm saturates the mexi-I and MCC 
signals, while mexi-III signals are still observable. 2D SD 1H NMR spectra with three SSPs 
applied at 2.9 ppm were acquired at B0 = 9.4 T from mexi-I, mexi-III, MCC and the model mexi 
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formulation (Figure 6E-H). The rows extracted from the 2D SD 1H NMR spectra at an indirect 
dimension shift of 9.7 ppm are shown in Figure 6I-L. As expected, only NMR signals from mexi-
III are visible in the formulation because the SSPs efficiently saturate both MCC and mexi-I NMR 
signals. These results illustrate that 1H SSNMR could be useful to selectively detect different 
polymorphic forms on the basis of their response to SSPs. However, a clear drawback of the 1H 
SSNMR experiments that mexi-I NMR signals could not be observed in this case because they are 
attenuated by the SSPs required to eliminate MCC NMR signals. This limitation could likely be 
overcome by increasing the static magnetic field and/or MAS frequency to increase 1H resolution, 
reduce spin diffusion and improve the selectivity of SSPs.  
Quantification of API Loading by 1H SSNMR. Finally, the ability of 1H SSNMR to quantify API 
loading in a formulation was also tested. It has previously been demonstrated that 13C CPMAS can 
be used to quantify API loading within a formulation based upon the comparison of peak 
intensities.7–11 1H SSNMR experiments were performed on physical mixtures of theo-II and MCC 
with variable loading of theo-II from 2 wt.% to 9.8 wt.% to investigate the possibility of using 1H 
SSNMR for quantification of APIs in formulations. Figure 7A shows a plot of the integrated 
intensity of the amine 1H NMR signal of theo-II measured with 1D SE-SD experiments as a 
function of the theo-II wt.%.  For the calibration experiments the recycle delay was fixed to 95 s 
which corresponds to 1.3 times the signal build-up time constant of 73 s measured for the theo-II 
amine signal. The SE pulse was placed on resonance with the theo-II amine signal and the spin 
diffusion spin-lock pulse was set to 20 ms in duration to maximize sensitivity by focusing signal 
into the amine peak. Figure 7A shows that there is a linear correlation between the theo-II 1H 
NMR signal intensity and the theo-II wt.% within the mixtures. Using the measured integrated 
intensities and the calibration equation, the average absolute error in the API loading was 0.36 
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wt.% and the average relative error was 9.9% of the expected API loading (Table S4). These 
experiments demonstrate fast MAS 1H SSNMR should be quantitative, provided the 1H NMR 
signal response to the SSP and SE pulses are first calibrated on standards with known API loading.  
 
Figure 7. A) Plot of integrated intensity of the amine 1H NMR signal of theo-II on different 
mixtures with MCC. Comparison of the 1D SE-SD 1H NMR signal intensities for the 
corresponding pure APIs and for B) 10 wt.% theo-I in MCC, C) a 12.5 wt.% mecl tablet, D) a 68 
wt.% phenaz tablet. The insets show the intensity scaling required to match the integrated intensity 
of high frequency API signals of the formulation to those of the pure API. The spectra are 
normalized for differences in number of scans. Data for A), B) and D) was obtained at B0 = 9.4 T 
and C) was obtained at B0 = 18.8 T.  
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Signal intensities were also used to estimate the loading of other APIs within formulations. 1D 
SE-SD 1H NMR integrated signal intensities were compared for samples of pure theo-I and a 10 
wt.% theo I – MCC physical mixture (Figure 7B). Based upon the integrated signal intensity the 
theo-I wt.% in the mixture was determined to be 11 wt.%, which is within 1 wt.% of the expected 
value. Comparison of the mexi-III signal intensity in 2D 1H SD experiments yields a 6.8 wt.% 
loading of mexi-III in the formulation, which is close to the expected value of 5.2 wt.% mexi-III 
(Figure 6K). Quantification was also attempted with 1D SE-SD 1H SSNMR experiments on pure 
and formulated mecl and phenaz (Figure 7). For the commercial mecl tablet an API loading of 
15.0 wt.% was determined, which is within 2.5 wt.% of the stated mecl loading of 12.5 wt.%. Note 
that different 1H T1 values were measured for mecl in bulk and dosage forms (Table S5). All NMR 
spectra of mecl were obtained with recycle delays of 1.3×T1 for optimal sensitivity. However, 
there is likely some uncertainty in the measured T1 values and this will affect the accuracy of 
quantification. Quantification could be improved by using longer recycle delays to minimize the 
contributions of longitudinal relaxation to signal differences. For the commercial phenaz tablet 
the API loading was measured to be 69 wt. % which is within 1 wt.% of the expected value of 68 
wt.%. The phenaz quantification was performed with 1D SE-SD experiments that used recycle 
delays of 5×T1. We anticipate that the accuracy of API quantification by 1H SSNMR could be 
further improved by using common practices such as adding an internal standard to the sample,7 
weighing the amount of sample packed into the rotor and/or limiting the sample to the central 
portion of the rotor to minimize rf homogeneity effects.  
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CONCLUSIONS 
In summary, straightforward and highly sensitive 1D and 2D fast MAS 1H SSNMR experiments 
can be used to rapidly identify the solid forms of dilute APIs within dosage forms. The sensitivity 
of 1H SSNMR greatly exceeds that of 13C SSNMR, typically enabling one to three order of 
magnitude reductions in experiment times. Diagnostic 1H SSNMR spectra of dilute APIs within 
formulations can typically be obtained in minutes, even when the API has unfavorable T1 
relaxation times and low API loading, whereas 13C SSNMR spectra would require hours or days 
of signal averaging to obtain NMR spectra of similar SNR. 1H SSNMR can permit the routine 
detection of many APIs that have a long 1H T1 and/or APIs that are very dilute in a formulation. 
For theo and mexi the 1H SSNMR spectra of different crystalline forms are distinct, allowing 
polymorphic forms to be identified and detected on the basis of 1H chemical shifts or on the basis 
of differential response to saturation and excitation pulses. Experiments on theo mixtures and other 
samples demonstrate that 1H SSNMR spectra are quantitative after calibration on the individual 
components of the formulation.  
While many pharmaceutical samples are amenable to characterization using 1H SSNMR 
experiments, such methods may not be applicable or useful for all APIs, as was observed for pheny 
and mexi-I. In cases where the API lacks high frequency 1H NMR signals and/or has a poorly 
resolved 1H NMR spectrum, both SSPs and SE pulses will be inefficient and it will be challenging 
to detect API 1H NMR signals from the formulation and/or obtain meaningful structural 
information about the API. However, these limitations have some obvious solutions. The 
resolution of 1H SSNMR spectra and SD rates can be reduced by using higher magnetic fields 
and/or faster MAS frequencies. Probes capable of MAS frequencies greater than 100 kHz are 
becoming widespread and should allow APIs with high frequency 1H chemical shifts below 10 
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ppm to be studied.27,34 Alternatively, DQ NMR experiments can provide improved resolution and 
shift discrimination,41,42 at the expense of reduced sensitivity. While the focus of the current work 
has been on pharmaceuticals, the methods described here should also be applicable to study other 
complex mixtures of organic solids.  
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SUPPORTING INFORMATION 
Additional NMR spectra, experimental details and Bruker pulse programs. The Supporting 
Information is available free of charge on the ACS Publications website. 
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